Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$4.65 USD
-0.36 (-7.10%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $4.64 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Ocular Therapeutix (OCUL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$15.44 | $24.00 | $11.00 | 208.80% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Ocular Therapeutix comes to $15.44. The forecasts range from a low of $11.00 to a high of $24.00. The average price target represents an increase of 208.8% from the last closing price of $5.00.
Analyst Price Targets (9 )
Broker Rating
Ocular Therapeutix currently has an average brokerage recommendation (ABR) of 1.22 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.22 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, eight are Strong Buy, representing 88.89% of all recommendations. A month ago, Strong Buy represented 88.89%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.22 | 1.22 | 1.22 | 1.22 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/13/2024 | H.C. Wainwright & Co. | Yi Chen | Strong Buy | Strong Buy |
3/12/2024 | JMP Securities | Jonathan Wolleben | Strong Buy | Strong Buy |
2/26/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
12/12/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
10/4/2023 | Berenberg Bank | Caroline H Palomeque | Not Available | Strong Buy |
9/14/2023 | Robert W. Baird & Co. | Colleen M Kusy | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.22 |
ABR (Last week) | 1.22 |
# of Recs in ABR | 9 |
Average Target Price | $15.44 |
LT Growth Rate | 12.00% |
Industry | Medical - Drugs |
Industry Rank by ABR | 147 of 252 |
Current Quarter EPS Est: | -0.18 |